Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program

- The Expanded Access Program is funded by a grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS for ALS patients who... | April 4, 2023

Related Keywords

New York ,United States ,Anthony Marciano ,Mike Moyer ,Human Services ,Drug Administration ,Nasdaq ,Partnership For Rare Neurodegenerative Diseases ,Exchange Commission ,Lifesci Advisors ,National Institutes Of Health ,Department Of Health ,Prnewswire Seelos Therapeutics Inc ,National Institute Of Neurological Disorders ,Access Program ,Seelos Therapeutics Inc ,Expanded Access Program ,National Institute ,Neurological Disorders ,Accelerating Access ,Critical Therapies ,Public Law ,National Institutes ,Public Private Partnership ,Rare Neurodegenerative Diseases ,Transcription Factor ,Amyotrophic Lateral Sclerosis ,Acute Suicidal Ideation ,Major Depressive Disorder ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Sci Advisors ,Seelos Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,The ,Xpanded ,Access ,Program ,Us ,Funded ,Y ,Rant ,Rom ,Ational ,Institute ,F ,Neurological ,Disorders ,End ,Stroke ,Under ,Ccelerating ,O ,Critical ,Therapies ,Or ,Ls ,Atients Seel Us81577f1093 ,